
- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact



ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.

-
General Endocrinology
Katergari SA, Milousis A., Passadaki T., Mantatzis M., Tripsianis G., Asimakopoulos B., Nikolettos N., Papachristou DN
Postprandial Free Fatty Acids Are Related to Total Visceral and Retroperitoneal Fat in Dibetic MenActa Endo (Buc) 2013 9(2): 201-218 doi: 10.4183/aeb.2013.201
AbstractObjective. To evaluate circulating FFAs in relation to glucose and insulin metabolism and to different fat compartments in men with and without diabetes. Patients and Methods. Thirtythree men with uncomplicated type 2 diabetes mellitus (T2DM) and 28 controls underwent an oral fat load and were studied at baseline and for 5 hours postprandially for serum FFAs, glucose and insulin. Abdominal fat distribution and gluteal fat accumulation were evaluated by anthropometrics and axial MRI images. Insulin resistance and sensitivity were estimated by HOMA and Matsuda index respectively. Results. Fasting and postprandial FFAs were higher in diabetics (p=0.007) despite similar fat accumulation and distribution between groups. Postprandial FFAs correlated positively with postprandial glucose, and fasting and postprandial insulin levels (p< 0.05) in controls, and with fasting and postprandial insulin levels (p< 0.05 and p < 0.01 respectively) in diabetics. Postprandial FFAs were positively correlated to HOMA (p<0.01) and negatively to Matsuda index (p<0.05), and positively to total visceral and retroperitoneal fat,the strongest association observed at L2- L3 (p<0.05 and p<0.001 respectively) in diabetics. Conclusions. Diabetics have higher serum FFAs, despite similar levels of adiposity and fat distribution. Interestingly, postprandial FFAs correlate strongly and positively with total visceral fat, underlying the importance of visceral fat in metabolic abnormalities in diabetes. -
Case Report
Balmes E, Burcea A, Belgun M, Alexandrescu D, Badiu C
Marine-Lenhart syndrome. Case report and literature reviewActa Endo (Buc) 2007 3(2): 201-208 doi: 10.4183/aeb.2007.201
AbstractGraves’ disease and toxic nodular goiter both cause thyrotoxicosis by different pathophysiological mechanisms. Rare cases associates both etiologies are undertaken by the diagnosis of Marine-Lenhart syndrome. A woman aged 38, with Graves’ unilateral ophthalmopathy and a solitary, echo-dense thyroid nodule, developed thyrotoxicosis within the following 3 months. The diagnosis was certified by suppressed TSH (0.002 mIU/L), high fT4 (5.6 ng/mL) associated with elevated TRAb (3.5 IU/L), moderately elevated TPOAb (63.1 IU/mL) and ATGl (248 IU/mL). The thyroid radioiodine scan revealed a solitary hot nodule in the left lobe with an elevated radioiodine uptake. Methyl prednisolone was started by oral and pulse therapy, with stabilization of ophthalmopathy within 5 months. After four months with antithyroid drug therapy followed by radioiodine (25 mCi 131I), the thyroid scan revealed diffuse radioiodine uptake. Nine months after radioiodine therapy, the patient was in clinical and biochemical hypothyroidism and substitutive therapy was instituted. A broad literature review suggested that in such rare cases, underlying autoimmune mechanisms might be involved in the development of thyroid nodules with variable function and proliferation activity. -
Endocrine Care
Fica SV, Albu A, Vadareanu F, Barbu C, Bunghez R, Nitu L, Marinescu D
Endocrine disorders in ?-thalassemia major: cross-sectional dataActa Endo (Buc) 2005 1(2): 201-212 doi: 10.4183/aeb.2005.201
Abstract ReferencesChronic transfusion regimen and chelating therapy has dramatically improved the life expectancy of thalassemic patients. The aim of this study was to assess the prevalence of endocrine disturbances in patients with beta-thalassemia major. Subjects were 64 patients with a mean age of 19.45 ? 6.82 years found in haematological care at the National Institute of Transfusional Haematology. All the patients were evaluated clinically and biologically. LH, FSH, estradiol, testosterone, TSH, free T4, insulin were measured by chemiluminescence; mean ferritin value was used to assess iron overload. Fifty one patients (79.68%) -27 male and 24 female in our group were at pubertal or adult age. Eleven boys (40.74%) had delayed puberty, 10 (37%) arrested puberty and 4 (14.8%) had reached complete sexual maturation. In the female group, 6 (25%) had delayed puberty, 4 (16.66%) arrested puberty and 14 (58.32%) reached full sexual development. Half of both the male and female patients with complete sexual maturation had hypogonadotropic hypogonadism at the evaluation moment. Moreover, 34 (53.12%) of our patients had pathological short stature, 11 (17.18%) primary hypothyroidism, 5 (7.8%) hypoparathyroidism, 3 (4.68%) diabetes mellitus and 6 (9.37%) insulin resistance. We found a significantly higher mean ferritin value in patients with endocrine disturbances of any type compared to subjects without endocrinopathies. In conclusion, our data showed that hypogonadism and short stature were the most frequently found endocrine disturbances. Early form of hypogonadism had a major clinical impact on sexual development and final height. These results suggest that early endocrine evaluation and treatment are necessary in order to improve the quality of life of these patients.1. Olivieri NF, Brittenham GM. Iron-Chelating Therapy and the Treatment of Thalassemia. Blood 1997; 89:739-761.2. Italian Working Group on Endocrine Complication in Non-endocrine Diseases. Multicenter study on prevalence of endocrine complications in thalassaemia major. Clinical Endocrinology 1995; 42:581-586.3. Guidelines for the Clinical Management of Thalassaemia:Thalassaemia International Federation, 2002. (Accessed July 16, 2005, at site <http://www.thalassaemia.org.cy/books/book1/ch1-ch2.doc).4. Talmaci R, Traeger-Synodinos J, Kanavakis E, Coriu D, Colita D, Gavrila L. Scanning of β-globin gene for identification of β-thalassemia mutation in Romanian population. J Cell Mol 2004; 2:232-240. [CrossRef]5. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM. CDC Growth charts: United States. Advance Data from Vital and Health Statistics of the Centers for Disease Control and Prevention/National Center for Health Statistics 2000; No 314.6. Fica S, Barbu C, Vladareanu F, Rotaru R, Albu A. The effects of chronic transfusional regimens on sexual development among homozygous beta thalassemic parients. Abstracts of the 12th International Congress of Endocrinology. Lisbon 2004.7. Shalitin S et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005;74:93-100. [CrossRef]8. Shamshirsaz AA et al. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocrine Disorders 2003; 3:4. [CrossRef]9. Prototonotariou A, Katopodi A, Zervas A, Livadas S, Konstantellou E, Tolis G. Homozygous β-thalassemia and the gonad. Abstracts of the 3rd International Conference on Recent Developments on the Diagnosis and Therapy of Endocrine and Metabolic Proble10. Bergeron C, Kovacs K. Pituitary siderosis: A histologic, immunocytologic, and ultrastructural study. Am J Pathol 1978; 9:295-309.11. Bronspeigel-Weintrob N, Olivieri NF, Tyler BJ, Andrews D, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990; 323:713-719. [CrossRef]12. Sklar CA, Lew LQ, Yoon DJ, David R. Adrenal function in thalassemia major following long term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. Am J Dis Child 1990; 141:327-13. Maurer HS, Lloyd-Still JD, Ingrisano C, Gonzalez-Crussi F, Honig CR. A prospective evaluation of iron chelation therapy in children with severe beta-thalassaemia: A six-year study. Am J Dis Child 1988; 142:287-292.14. Borgna-Pignatti et al. Growth and sexual maturation in thalassemia major. J Pediatr 1985;106:150-155. [CrossRef]15. Chatterjee R, Katz M, Cox TF, Porter JB. Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed secondary amenorrhea. Clin Endocrinol 1993; 39:287-290. [CrossRef]16. De Sanctis V, Wonke B. Growth and endocrine complications in thalassaemia. Roma: Mediprint 1998;17-1917. Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High-dose deferoxamine as a cause of growth failure in thalassaemic patients. Eur J Haematol 1988; 40:380-381. [CrossRef]18. DeVirgilis S et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988; 113:661-669. [CrossRef]19. Olivieri NF et al. Growth failure and bony changes induced by deferoxamine. Am J Ped Hematol Oncol 1992; 14:48-56. [CrossRef]20. Arcasoy A et al. Effects of zinc supplementation on linear growth in beta thalassemia (a new approach). Am J Hematol 1987; 24:127-136. [CrossRef]21. Leek JC, Vogler JB, Gershwin ME, Golub MS, Hurley LS, Hendrickx AG. Studies of marginal zinc deprivation in rhesus monkeys. Fetal and infant skeletal effects. Am J Clin Nutr 1984; 40:1203-1212.22. Nishi Y, Hatano S, Aihara K, Fujie A, Kihara M. Transient partial growth hormone deficiency due to zinc deficiency. J Am Coll Nutr 1989; 8:93-97.23. Bozzola M et al. Effect of human chorionic gonadotropin on growth velocity and biological growth parameters in adolescents with thalassaemia major. Eur J Pediatr 1989;148:300-303. [CrossRef]24. Soliman A. Growth hormone (GH) response to provocation, circulating insuline-like growth factor-1 (IGF-1) and IGF-binding protein-3 concentrations, IGF-1 generation tests and clinical response to GH therapy in children with beta-thalassemia. Abstracts o25. Caruso-Nicoletti M et al. Management of puberty for optimal auxological results in betathalassaemia major. J Pediatr Endocrinol Metab 2001;14:939-944.26. Aleem A, Al-Momen A, Al-Harakati MS, Hassan A, Al-Fawaz I. Hypocalcemia due to hypoparathyroidism in β-thalassemia major patients. Ann Saudi Med. 2000; 20:364-366.27. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988; 63:58-62. [CrossRef]28. Dmochowski K, Finegood DT, Francombe WH, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993; 77:478-483. [CrossRef]29. Cavallo-Perin P, Pacini B, Cerutti F, Bessone A, Condo C, Sacchetti L, Piga A, Pagano G. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 1995; 44:281-286.30. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331:567-573. [CrossRef]31. Olivieri NF et al. Survival of medically treated patients with homozygous thalassemia. N Engl J Med 1994; 331:574-578. [CrossRef] -
Endocrine Care
Bolu F, Bolu S
Congenital Hypothyroidism Screening Results in the Turkish Province of Adiyaman in 2015-2020Acta Endo (Buc) 2024 20(2): 201-206 doi: 10.4183/aeb.2024.201
AbstractContext. Congenital hypothyroidism (CH) is one of the most common preventable causes of intellectual disability, and can be diagnosed in the early period through neonatal screening programs. Objective. The purpose of this study was to determine the prevalence of CH and recall rates in the province of Adıyaman. Design. This retrospective study evaluated the data of newborn screening program in Adıyaman province between January 2015 and December 2020. Subjects and Methods. The thyroid-stimulating hormone (TSH) cut-off value in the screening program is 5.5 mIU/L and TSH values lower than 5.5 mIU/L are regarded as normal. Babies with TSH levels exceeding 5.5 mIU/L were defined as ‘recalled’. TSH measurements and clinical diagnoses of the recalled babies were evaluated. Results. TSH was <5.5 mIU/L in 62270 (90.08%) of the newborns, 5.5-20 mIU/L in 6114 (8.84%), and >20 mIU/L in 742 (1.07%). Venous T4-TSH values were normal in 673 of the 742 babies with TSH levels exceeding 20 mIU/L, while 63 babies were diagnosed with CH. Heel blood results were normal in 5880 of the 6114 babies with TSH levels of 5.5-20 mIU/L and for whom repeat heel blood was requested. TSH levels in repeat heel blood were >5.5 mIU/L in 184 babies and 93 of them were diagnosed with hypothyroidism. The recall rate among babies undergoing heel blood TSH measurement in the province of Adıyaman was 9.9%. 156 babies were started on thyroid replacement therapy with diagnoses of CH. The incidence of babies diagnosed with hypothyroidism was 1/443. Conclusion. According to the CH screening results, the recall rate and incidence of CH in the province of Adıyaman were higher than the global general figures. Both the low TSH threshold value employed in neonatal hypothyroidism screening and the province falling within the iodine deficiency region may account for this. -
Endocrine Care
Aydin C, Ersoy R, Ozdemir D, Cuhaci N, Arpaci D, Usluogullari CA, Ustu Y, Baser H, Dirikoc A, Cakir B
Comparison of Growth Hormone Suppression Response after Oral and Intravenous Glucose Tolerance Tests in Healthy AdultsActa Endo (Buc) 2015 11(2): 202-207 doi: 10.4183/aeb.2015.202
AbstractObjective. Personal discrepancies in gastrointestinal physiology might influence responses to GH suppression during OGTT. We aim to compare growth hormone (GH) response during oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT). Methods. Data of 18 healthy volunteers were analyzed in the study. Subjects were firstly evaluated with standard 75-g OGTT. In subjects with serum glucose <100 mg/dL at basal state and <140 mg/dL at 120th minute of oral loading, IVGTT was performed after at least 3 days. Serum glucose, insulin and GH levels were measured during two tests. Results. Basal GH levels had a wide distribution ranging from 0.00005 μg/L to 0.768 μg/L (median 0.0145 μg/L). Mean nadir GH level during OGTT was obtained at 60th minute and it was 0.0376 μg/L(range 0.00011-0.387, median 0.0016 μg/L, SD: 0.095, SEM: 0.038). Nadir GH level during IVGTT was observed at 10th minute and it was 0.112 μg/L(range 0.0005-0.770 μg/L, median 0.0053 μg/L, SD: 0.242, SEM: 0.057). There was a statistically significant difference between nadir GH levels obtained during IVGTT and OGTT (p=0.028). Conclusions. We found that mean nadir GH level was significantly higher during IVGTT in healthy subjects. This is a preliminary study and further large scale studies are required to suggest that IVGTT may be used in the diagnosis and follow-up of patients with acromegaly as an alternative to or instead of OGTT. -
Endocrine Care
Gunhan HG, Elbasan O, Imre E, Gogas Yavuz D
Lipodystrophy Frequency According to Insulin Treatment Regimen in Type 2 Diabetic Patients: is Insulin Injection Frequency Matters in Analog Insulin Era?Acta Endo (Buc) 2022 18(2): 202-208 doi: 10.4183/aeb.2022.202
AbstractObjectives. We aimed to determine lipodystrophy frequency according to insulin treatment regimen and insulin injection frequency in type 2 diabetic patients. Methods. A total of 345 type 2 diabetic patients under insulin treatment for at least one year were included in this cross-sectional study. Patients were examined for presence of lipodystrophy, insulin injection frequency and dosage. Lipodystrophy was evaluated with visual inspection and palpation of all injection sites. Patients were evaluated into three categories according to daily insulin dose requirement: Group 1= Standard-dose insulin users 0.6 U/ kg/day; Group 2= Medium-dose insulin users 0.61-1.9 U/kg/ day, Group 3= High-dose insulin users ≥2 U/kg/day. Results. Lipodystrophy was seen in 28% of the patients. Lipodystrophy was significantly higher in group 3. There was no significant difference between the groups in terms of lipodystrophy size. Duration of insulin treatment, daily total insulin dose, daily insulin dose per weight and number of daily insulin injections were significantly higher in the group with lipodystrophy. Daily injection number of long-acting, rapidly-acting analog and total insulin injections were significantly higher in group 3 than group 1 and 2. Number of daily insulin injections and lipodystrophy frequency were significantly higher in basalbolus insulin user group. Multivariate analysis showed that insulin injection frequency is the independent risk factor for lipodystrophy. Conclusion. Lipodystrophy is still a clinical problem in patients with high-dose insulin requirement and frequent insulin injections. Reducing daily insulin requirement and daily number of injections should be given priority in the management of patients to prevent the development of lipodystrophy. -
Editorial
Mihali CV, Petrescu MC, Mandrutiu I, Bechet D, Nistor TV, Turcu V, Ardelean A, Benga G
Comparison of Plasma Phenylalanine Determination by Densitometry of Thin-Layer Chromatograms and by High Performance Liquid Chromatography in Relation with the Screening of PhenylketonuriaActa Endo (Buc) 2017 13(2): 203-208 doi: 10.4183/aeb.2017.203
AbstractObjective. To compare two chromatographic methodologies for determination of plasma phenylalanine (Phe) and their usefulness for diagnosing hyperphenylalaninemia (HPA) and phenylketonuria (PKU). Methods. The plasma amino acids were isolated and concentrated from blood collected from infants with HPA detected by newborn screening. The plasma Phe was determined in parallel by HPLC and by image-densitometry of 2D-TLC plates. Results. Typical examples of 2D-TLC plates and HPLC chromatograms from infants with HPA and PKU are presented and evaluated. The Phe spot was visible on 2D - TLC plates at Phe concentrations higher than 300 μmol/L. The standard calibration curve traced after imagedensitometry of the Phe spot presented high dispersion of values at each concentration of Phe, high SD values, the equation of the curve having a low R-squared value (0.862). In contrast, the standard calibration curve obtained by HPLC shows linearity on the range of concentrations from 100 - 16,000 μmol/L, extremely small SD values, the equation of the curve has a very high R-squared value (0.999). Conclusions. The HPLC methodology is appropriate to confirm HPA detected by newborn or selective screening of PKU. The 2D - TLC methodology is adequate to detect patients with severe PKU. -
Endocrine Care
Larg MI, Barbus E, Gabora K, Pestean C, Cheptea M, Piciu D
18F-FDG PET/CT in Differentiated Thyroid CarcinomaActa Endo (Buc) 2019 15(2): 203-208 doi: 10.4183/aeb.2019.203
AbstractAim. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) become an important tool in oncology by combining the metabolic information from 18F-FDG PET with the morphological information of CT. The main objective of this study was to assess the diagnostic value of PET/CT in patients with differentiated thyroid carcinoma (DTC). Material and Methods. We analyzed 173 PET/CT scans of patients with DTC presenting elevated thyroglobulin (Tg) levels, negative Tg-antibodies levels, negative Iodine-131 whole-body scanning (I-131 WBS) and without any signs of clinical or other imaging technique for tumor recurrence/metastases. Results. PET/CT scans were positive in 38% of cases (65/173). The sensitivity, specificity, positive predictive values and the accuracy of PET/CT imaging were 88.09%, 98.6%, 93.1% respectively 96.53%. After the PET/CT scan 29 patients underwent surgery, 24 of them continued radio-iodine therapy, 5 patients initiated tyrosine kinase inhibitors treatment and external radiotherapy. Conclusion. 18F-FDG PET/CT is a valuable imaging technique which has the capability of identifying those cases of thyroid recurrence/metastases with elevated Tg levels and negative I-131 WBS. The treatment strategy was changed in 89.2% cases of positive PET/CT scans which shows us that 18F-FDG PET/CT imaging should be integrated into the follow-up programs for DTC patients. -
General Endocrinology
Kocaoglu C, Atabek M.E, Cayci M, Kurku H, Ozel A
The Effect of Helicobacter Pylori Infection on Plasma Ghrelin and on AnthropometrY Dyspeptic ChildrenActa Endo (Buc) 2014 10(2): 203-210 doi: 10.4183/aeb.2014.203
AbstractBackground. Plasma level of ghrelin is possibly reduced in Helicobacter pylori infection and may account for the resultant failure to thrive. Objective. To investigate relationships between Helicobacter pylori infection, and plasma level of ghrelin, anthropometric measurements, appetite, educational and economical status of parents. Methods. Ninety-four children were screened for Helicobacter pylori infection with C-14 urea breath test. Anthropometric measurements were performed in Helicobacter pylori (+) and (-) groups. Plasma ghrelin was measured. Parents were asked to fill out the questionnaire prepared by the researcher on the number of family members, parents’ level of education, monthly income and children’s status for appetite. Results. Plasma ghrelin was lower in Helicobacter pylori (+) group (20.00 ± 22.10 ng/mL), compared to Helicobacter pylori (-) group (79.72 ± 78.13 ng/mL). The percentiles of measurements for height, weight and body mass index were higher in Helicobacter pylori (-) group. Results of C-14 urea breath test were negatively correlated with height, weight and body mass index; however, no correlation was detected between the results of C-14 urea breath test, and plasma ghrelin, number of family members, levels of parents’ education and income. A negative correlation was observed between the results of C-14 urea breath test and appetite. Conclusions. Helicobacter pylori infection is considered to play a restricting role in growth potential by decreasing ghrelin level in children. Moreover, the existence of a negative correlation between the results of C-14 UBT, and weight, height and body mass index suggests a possible link between Helicobacter pylori infection and poor growth. -
Endocrine Care
Fica SV, Lazar A, Albu A, Barbu C, Grigorescu M
The impact of hyperthyroidism on glycemic control in patients with diabetes mellitusActa Endo (Buc) 2006 2(2): 203-212 doi: 10.4183/aeb.2006.203
AbstractAim: to evaluate the impact of hyperthyroidism on glycemic control among patients with diabetes mellitus (DM).\r\nResearch design and methods: This retrospective study included patients with hyperthyroidism and DM admitted in Endocrinology, Nutrition Diseases and Diabetes Department of Elias University Emergency Hospital. We evaluated 37 patients (35 women/ 2 men), with a mean age of 54.7?15.3 years and duration of diabetes 8.1?7.49 years; 20 patients with Graves diseases (54%), 10 with toxic multinodular goiter (27%), 5 with autonomous hyperfunctioning adenoma (13%) and 2 with amiodarone induced hyperthyroidism (5.4%). Clinical data were recorded for all our patients, as well as thyroid ultrasound exploration, laboratory analyses (glycosylated hemoglobin, free thyroxine FT4, triiodothyronine T3, thyroid stimulating hormone TSH).\r\nResults: Diabetes control was achieved with: insulin in 23 (62%) patients, antidiabetic oral agents in 9 (24%) and solely diet in 5 patients (13.5%). Hyperthyroid patients had a mean value of glycosylated hemoglobin of 9.3%?2.4% (poor glycemic control) versus 7.2%?1.6% after the treatment of hyperthyroidism. Among insulin-treated patients, the average need of insulin in hyperthyroid status was 0.72 u/kg versus 0.55 u/kg when the patients became euthyroid (p<0.01). We found a significant association between type 1 diabetes mellitus and Graves’ disease compared to toxic multinodular goiter (80% vs 50%, p<0.01).\r\nConclusions: The presence of hyperthyroidism aggravates glycemic control of the patients with diabetes mellitus and increases insulin need in insulin-treated patients. Once the thyroid function was stable, the insulin need decreased significantly (p<0.01). Hyperthyroidism should be radically treated to obtain a good glycemic control. Type 1 diabetes is significantly associated to Graves’s disease by an autoimmune mechanism.